Alkermes plc. (ALKS) Spending and interest coverage
- R&D / revenue · 12 months: Value 23.45%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 7.10%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 23.45% | Research and development expense / revenue. Period ending 2026-06-30. $391.04M ÷ $1.67B × 100 ≈ 23.45% |
| Stock-based compensation / revenue · 12 months | 7.10% | Share-based compensation / revenue. Period ending 2026-06-30. $118.41M ÷ $1.67B × 100 ≈ 7.10% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 391.04M USD | Research and Development Expense |
| Revenue | 1.67B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 118.41M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 117.26M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $391.04M | $1.67B | $118.41M | $117.26M | (m) | 23.45% | 7.10% | (m) | (m) |
| 2026-03-31 | $355.49M | $1.56B | $112.24M | $191.88M | (m) | 22.75% | 7.18% | (m) | (m) |
| 2025-12-31 | $323.96M | $1.48B | $98.72M | $253.96M | (m) | 21.95% | 6.69% | (m) | (m) |
| 2025-09-30 | $289.10M | $1.52B | $93.19M | $358.54M | (m) | 19.00% | 6.13% | (m) | (m) |
| 2025-06-30 | $267.25M | $1.51B | $91.06M | $374.21M | (m) | 17.75% | 6.05% | (m) | (m) |
| 2025-03-31 | $249.53M | $1.51B | $86.69M | $391.12M | (m) | 16.48% | 5.73% | (m) | (m) |
| 2024-12-31 | $245.33M | $1.56B | $96.64M | $420.64M | (m) | 15.75% | 6.20% | (m) | (m) |
| 2024-09-30 | $261.08M | $1.51B | $101.73M | $312.58M | (m) | 17.35% | 6.76% | (m) | (m) |
| 2024-06-30 | $266.07M | $1.51B | $103.11M | $297.02M | $23.99M | 17.64% | 6.84% | 12.38× | Reported |
| 2024-03-31 | $274.65M | $1.73B | $111.02M | $468.40M | $23.72M | 15.91% | 6.43% | 19.75× | Reported |
| 2023-12-31 | $270.81M | $1.66B | $100.91M | $414.12M | $23.03M | 16.28% | 6.07% | 17.98× | Reported |
| 2023-09-30 | $396.15M | $1.59B | $101.55M | $214.97M | $21.75M | 24.91% | 6.38% | 9.88× | Reported |
| 2023-06-30 | $399.44M | $1.46B | $103.68M | $110.48M | $19.29M | 27.32% | 7.09% | 5.73× | Reported |
| 2023-03-31 | $391.53M | $1.12B | $98.55M | $-163.17M | $15.98M | 34.93% | 8.79% | -10.21× | Reported |
| 2022-12-31 | $393.84M | $1.11B | $94.25M | $-142.26M | $13.04M | 35.42% | 8.48% | -10.91× | Reported |
| 2022-09-30 | $387.63M | $1.13B | $86.79M | $-119.30M | $10.68M | 34.26% | 7.67% | -11.17× | Reported |
| 2022-06-30 | $405.61M | $1.17B | $86.34M | $-78.32M | $9.56M | 34.57% | 7.36% | -8.19× | Reported |
| 2022-03-31 | $410.21M | $1.20B | $90.51M | $-39.44M | $9.60M | 34.16% | 7.54% | -4.11× | Reported |
| 2021-12-31 | $406.53M | $1.17B | $87.62M | $-29.29M | $11.22M | 34.63% | 7.47% | -2.61× | Reported |
| 2021-09-30 | $420.26M | $1.13B | $93.49M | $-62.40M | $10.68M | 37.21% | 8.28% | -5.84× | Reported |
| 2021-06-30 | $396.83M | $1.10B | $90.51M | $-53.41M | $10.06M | 36.07% | 8.23% | -5.31× | Reported |
| 2021-03-31 | $393.58M | $1.04B | $85.80M | $-91.49M | $9.77M | 37.70% | 8.22% | -9.36× | Reported |
| 2020-12-31 | $394.59M | $1.04B | $90.16M | $-112.43M | $8.66M | 37.99% | 8.68% | -12.98× | Reported |
| 2020-09-30 | $480.64M | $1.17B | $86.67M | $-91.63M | $9.99M | 41.03% | 7.40% | -9.18× | Reported |
| 2020-06-30 | $493.33M | $1.16B | $90.78M | $-134.59M | $11.56M | 42.47% | 7.81% | -11.64× | Reported |
| 2020-03-31 | $503.54M | $1.19B | $96.17M | $-136.85M | $12.96M | 42.17% | 8.05% | -10.56× | Reported |
| 2019-12-31 | $512.83M | $1.17B | $100.98M | $-175.48M | $13.60M | 43.80% | 8.62% | -12.90× | Reported |
| 2019-09-30 | $423.65M | $1.07B | $108.90M | $-165.53M | $13.88M | 39.45% | 10.14% | -11.92× | Reported |
| 2019-06-30 | $417.24M | $1.07B | $107.24M | $-149.06M | $13.84M | 39.09% | 10.05% | -10.77× | Reported |
| 2019-03-31 | $419.63M | $1.09B | $109.93M | $-113.24M | $13.45M | 38.42% | 10.06% | -8.42× | Reported |
| 2018-12-31 | $425.41M | $1.09B | $105.36M | $-99.13M | $15.44M | 38.88% | 9.63% | -6.42× | Reported |
| 2018-09-30 | $420.92M | $1.05B | $96.62M | $-93.31M | $15.15M | 39.94% | 9.17% | -6.16× | Reported |
| 2018-06-30 | $424.07M | $1.02B | $91.04M | $-94.51M | $14.94M | 41.47% | 8.90% | -6.33× | Reported |
| 2018-03-31 | $416.40M | $936.75M | $82.79M | $-138.92M | $14.73M | 44.45% | 8.84% | -9.43× | Reported |
| 2017-12-31 | $412.89M | $903.37M | $83.92M | $-147.90M | $12.01M | 45.71% | 9.29% | -12.32× | Reported |
| 2017-09-30 | $398.02M | $841.52M | $83.12M | $-177.27M | $13.71M | 47.30% | 9.88% | -12.93× | Reported |
| 2017-06-30 | $393.06M | $804.37M | $87.36M | $-200.04M | $13.96M | 48.87% | 10.86% | -14.33× | Reported |
| 2017-03-31 | $390.91M | $780.70M | $91.31M | $-202.65M | $14.36M | 50.07% | 11.70% | -14.11× | Reported |
| 2016-12-31 | $387.15M | $745.69M | $94.40M | $-208.66M | $14.89M | 51.92% | 12.66% | -14.01× | Reported |
| 2016-09-30 | $391.21M | $695.28M | $97.48M | $-252.19M | $13.31M | 56.27% | 14.02% | -18.94× | Reported |
| 2016-06-30 | $384.32M | $667.69M | $109.02M | $-268.47M | $13.26M | 57.56% | 16.33% | -20.24× | Reported |
| 2016-03-31 | $375.20M | $623.89M | $104.27M | $-273.88M | $13.25M | 60.14% | 16.71% | -20.66× | Reported |
| 2015-12-31 | $344.40M | $628.34M | $97.34M | $-224.30M | $13.25M | 54.81% | 15.49% | -16.93× | Reported |
| 2015-09-30 | $325.15M | $640.40M | $87.81M | $-172.93M | $13.26M | 50.77% | 13.71% | -13.04× | Reported |
| 2015-06-30 | $310.86M | $647.74M | $66.03M | $-128.25M | $13.29M | 47.99% | 10.19% | -9.65× | Reported |
| 2015-03-31 | $290.18M | $649.79M | $63.49M | $-98.56M | $13.36M | 44.66% | 9.77% | -7.38× | Reported |
| 2014-12-31 | $272.04M | $618.79M | $59.58M | $-87.14M | $13.43M | 43.96% | 9.63% | -6.49× | Reported |
| 2014-09-30 | $246.33M | $598.11M | $56.63M | $-65.61M | $13.53M | 41.18% | 9.47% | -4.85× | Reported |
| 2014-06-30 | $214.01M | $577.92M | $57.36M | $-36.75M | $13.65M | 37.03% | 9.92% | -2.69× | Reported |
| 2014-03-31 | $180.26M | $563.12M | $46.83M | $-399.00K | $13.73M | 32.01% | 8.32% | -0.03× | Reported |
| 2013-12-31 | $163.93M | $596.33M | $41.29M | $34.48M | $21.85M | 27.49% | 6.92% | 1.58× | Reported |
| 2013-09-30 | $146.53M | $577.76M | $39.13M | $53.90M | $23.12M | 25.36% | 6.77% | 2.33× | Reported |
| 2013-06-30 | $135.67M | $561.94M | $35.36M | $63.20M | $42.29M | 24.14% | 6.29% | 1.49× | Reported |
| 2013-03-31 | $140.01M | $575.55M | $34.72M | $81.81M | $48.99M | 24.33% | 6.03% | 1.67× | Reported |
| 2012-12-31 | $149.40M | $542.60M | $33.92M | $5.16M | $47.61M | 27.53% | 6.25% | 0.11× | Reported |
| 2012-09-30 | $158.58M | $532.33M | $34.72M | $-25.07M | $53.37M | 29.79% | 6.52% | -0.47× | Reported |
| 2012-06-30 | $151.65M | $480.33M | $31.33M | $-42.25M | $38.28M | 31.57% | 6.52% | -1.10× | Reported |
| 2012-03-31 | $141.89M | $389.98M | $28.83M | $-88.28M | $28.11M | 36.38% | 7.39% | -3.14× | Reported |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $97.24M | $186.64M | $19.83M | $-45.63M | $3.30M | 52.10% | 10.63% | -13.84× | Reported |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | $95.36M | $178.28M | $13.92M | $-43.03M | $5.97M | 53.49% | 7.81% | -7.20× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |